Non-alcoholic fatty liver disease is a risk factor for the development of diabeticnephropathy in patients with type 2 diabetes mellitus

PLoS ONE

Volumn 10, Issue 11, 2015, Pages

  Jia, Guoyu ^a   Di, Fusheng ^a   Wang, Qipeng ^b   Shao, Jinshuang ^a   Gao, Lei ^a   Wang, Lu ^a   Li, Qiang ^a   Li, Nali ^a  

^a THIRD CENTRAL HOSPITAL OF TIANJIN   (China)

^b Fourth Central Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; FATTY ACID; HOMOCYSTEINE; OMENTIN 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; URIC ACID; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; ITLN1 PROTEIN, HUMAN; LECTIN; TUMOR NECROSIS FACTOR;

ADULT; ALBUMINURIA; ARTICLE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE SEVERITY; FAT CONTENT; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INCIDENCE; INSULIN RESISTANCE; INTRAABDOMINAL FAT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; RISK ASSESSMENT; RISK FACTOR; URIC ACID BLOOD LEVEL; AGED; BLOOD; COMORBIDITY; DIABETIC NEPHROPATHIES; LIVER; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY;

ADULT; AGED; ALBUMINURIA; COMORBIDITY; CYTOKINES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FATTY ACIDS, NONESTERIFIED; FEMALE; GLOMERULAR FILTRATION RATE; GPI-LINKED PROTEINS; HOMOCYSTEINE; HUMANS; INCIDENCE; INSULIN RESISTANCE; LECTINS; LIVER; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; RETROSPECTIVE STUDIES; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA; URIC ACID;

EID: 84958764638     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0142808     Document Type: Article

References (25)

1. Leite NC, Salles GF, Araujo AL, Villela-Nogueira CA, Cardoso CR. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int. 2009; 29: 113-119. doi: 10.1111/j.1478-3231.2008.01718.x PMID: 18384521
2. Gaggini M, Morelli M, Buzzigoli E, DeFronzo RA, Bugianesi E, Gastaldelli A. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients. 2013; 5: 1544-1560. doi: 10.3390/nu5051544 PMID: 23666091
3. Lu H, Zeng L, Liang B, Shu X, Xie D. High prevalence of coronary heart disease in type 2 diabetic patients with non-alcoholic fatty liver disease. Arch Med Res. 2009; 40: 571-575. doi: 10.1016/j. arcmed.2009.07.009 PMID: 20082871
4. Takeuchi Y, Ito H, Komatsu Y, Oshikiri K, Antoku S, Abe M, et al. Non-alcoholic fatty liver disease is an independent predictor for macroangiopathy in Japanese type 2 diabetic patients: a cross-sectional study. Intern Med. 2012; 51: 1667-1675. PMID: 22790124
5. Lv WS, Sun RX, Gao YY, Wen JP, Pan RF, Li L, et al. Nonalcoholic fatty liver disease and microvascular complications in type 2 diabetes. World J Gastroenterol. 2013; 19: 3134-3142. doi: 10.3748/wjg. v19.i20.3134 PMID: 23716995
6. Zhan YT, Zhang C, Li L, Bi CS, Song X, Zhang ST. Non-alcoholic fatty liver disease is not related to the incidence of diabetic nephropathy in Type 2 Diabetes. Int J Mol Sci. 2012; 13: 14698-14706. doi: 10. 3390/ijms131114698 PMID: 23203089
7. Targher G, Bertolini L, Rodella S, Zoppini G, Lippi G, Day C, et al. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. Diabetologia. 2008; 51: 444-450. PMID: 18058083
8. Targher G, Bertolini L, Chonchol M, Rodella S, Zoppini G, Lippi G, et al. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and retinopathy in type 1 diabetic patients. Diabetologia. 2010; 53: 1341-1348. doi: 10.1007/s00125-010-1720-1 PMID: 20369224
9. Orlic L, Mikolasevic I, Bagic Z, Racki S, Stimac D, Milic S. Chronic kidney disease and nonalcoholic Fatty liver disease-is there a link? Gastroenterol Res Pract. 2014; 2014: 847539. doi: 10.1155/2014/847539 PMID: 24729784
10. (1999) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. Geneva: World Health Organization.
11. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012; 142: 1592-1609. doi: 10.1053/j.gastro.2012.04.001 PMID: 22656328
12. Mogensen CE. Microalbuminuria, blood pressure and diabetic renal disease: origin and development of ideas. Diabetologia. 1999; 42: 263-285. PMID: 10096778
13. Nordstrand N, Gjevestad E, Dinh KN, Hofso D, Roislien J, Saltvedt E, et al. The relationship between various measures of obesity and arterial stiffness in morbidly obese patients. BMC Cardiovasc Disord. 2011; 11: 7. doi: 10.1186/1471-2261-11-7 PMID: 21284837
14. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care. 2000; 23: 57-63. PMID: 10857969
15. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006; 145: 247-254. PMID: 16908915
16. Xia MF, Yan HM, He WY, Li XM, Li CL, Yao XZ, et al. Standardized ultrasound hepatic/renal ratio and hepatic attenuation rate to quantify liver fat content: an improvement method. Obesity (Silver Spring). 2012; 20: 444-452.
17. Thoemmes FJ, Kim ES. A systematic review of propensity score methods in the social sciences. Multivariate Behavioral Research. 2011; 46: 90-118.
18. Mikolasevic I, Racki S, Bubic I, Jelic I, Stimac D, Orlic L. Chronic kidney disease and nonalcoholic Fatty liver disease proven by transient elastography. Kidney Blood Press Res. 2013; 37: 305-310. doi: 10. 1159/000350158 PMID: 24029696
19. Targher G, Bertolini L, Rodella S, Lippi G, Zoppini G, Chonchol M. Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis. Clin J Am Soc Nephrol. 2010; 5: 2166-2171. doi: 10.2215/CJN.05050610 PMID: 20724519
20. Furukawa M, Gohda T, Tanimoto M, Tomino Y. Pathogenesis and novel treatment from the mouse model of type 2 diabetic nephropathy. ScientificWorldJournal. 2013; 2013: 928197. doi: 10.1155/2013/928197 PMID: 23737732
21. Kim CH, Younossi ZM. Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Cleve Clin J Med. 2008; 75: 721-728. PMID: 18939388
22. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology. 2010; 51: 1820-1832. doi: 10.1002/hep.23594 PMID: 20432259
23. Chen J, Muntner P, Hamm LL, Fonseca V, Batuman V, Whelton PK, et al. Insulin resistance and risk of chronic kidney disease in nondiabetic US adults. J Am Soc Nephrol. 2003; 14: 469-477. PMID: 12538749
24. Chen J, Muntner P, Hamm LL, Jones DW, Batuman V, Fonseca V, et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med. 2004; 140: 167-174. PMID: 14757614
25. Milic S, Stimac D. Nonalcoholic fatty liver disease/steatohepatitis: epidemiology, pathogenesis, clinical presentation and treatment. Dig Dis. 2012; 30: 158-162. doi: 10.1159/000336669 PMID: 22722431